Levetiracetam and NOACs
The European Society of Cardiology recently published ‘The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation’.(1) This consensus and position paper is a very valuable source of information in clinical practice. However, the recommendation against the combination of levetiracetam and NOACs caused confusion and uncertainty in the neurological community.
Please continue here.
